NZ507964A - Substituted sulphonyl cyanamides - Google Patents

Substituted sulphonyl cyanamides

Info

Publication number
NZ507964A
NZ507964A NZ507964A NZ50796499A NZ507964A NZ 507964 A NZ507964 A NZ 507964A NZ 507964 A NZ507964 A NZ 507964A NZ 50796499 A NZ50796499 A NZ 50796499A NZ 507964 A NZ507964 A NZ 507964A
Authority
NZ
New Zealand
Prior art keywords
ischaemia
treatment
diseases
prophylaxis
cyanamides
Prior art date
Application number
NZ507964A
Other languages
English (en)
Inventor
Andreas Weichert
Hans Jochen Lang
Stefan Petry
Jan-Robert Schwark
Heinz-Werner Kleenmann
Sabine Faber
Hans-Willi Jansen
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NZ507964A publication Critical patent/NZ507964A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NZ507964A 1998-05-06 1999-04-30 Substituted sulphonyl cyanamides NZ507964A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820064A DE19820064A1 (de) 1998-05-06 1998-05-06 Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
PCT/EP1999/002940 WO1999057102A1 (de) 1998-05-06 1999-04-30 Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament

Publications (1)

Publication Number Publication Date
NZ507964A true NZ507964A (en) 2003-06-30

Family

ID=7866747

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507964A NZ507964A (en) 1998-05-06 1999-04-30 Substituted sulphonyl cyanamides

Country Status (26)

Country Link
US (1) US6573288B1 (enExample)
EP (1) EP1076651B1 (enExample)
JP (1) JP4546644B2 (enExample)
KR (1) KR20010043304A (enExample)
CN (1) CN1177829C (enExample)
AR (1) AR016255A1 (enExample)
AT (1) ATE293606T1 (enExample)
AU (1) AU756844B2 (enExample)
BR (1) BR9911009A (enExample)
CA (1) CA2331863A1 (enExample)
DE (3) DE19820064A1 (enExample)
DK (1) DK1076651T3 (enExample)
ES (1) ES2241326T3 (enExample)
HR (1) HRP20000746A2 (enExample)
HU (1) HU225377B1 (enExample)
ID (1) ID28020A (enExample)
IL (1) IL139264A (enExample)
NO (1) NO317886B1 (enExample)
NZ (1) NZ507964A (enExample)
PL (1) PL344041A1 (enExample)
PT (1) PT1076651E (enExample)
RU (1) RU2221789C2 (enExample)
SK (1) SK16582000A3 (enExample)
TR (1) TR200003248T2 (enExample)
WO (1) WO1999057102A1 (enExample)
ZA (1) ZA200006166B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
ITTO20060575A1 (it) * 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
TW215434B (enExample) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
ATE293606T1 (de) 2005-05-15
HRP20000746A2 (en) 2001-06-30
SK16582000A3 (sk) 2001-06-11
DK1076651T3 (da) 2005-08-15
IL139264A0 (en) 2001-11-25
IL139264A (en) 2004-07-25
NO317886B1 (no) 2004-12-27
CA2331863A1 (en) 1999-11-11
AU5947999A (en) 1999-11-23
CN1305463A (zh) 2001-07-25
NO20005549L (no) 2001-01-05
US6573288B1 (en) 2003-06-03
AR016255A1 (es) 2001-06-20
ES2241326T3 (es) 2005-10-16
ZA200006166B (en) 2001-09-26
AU756844B2 (en) 2003-01-23
ID28020A (id) 2001-05-03
EP1076651A1 (de) 2001-02-21
TR200003248T2 (tr) 2001-03-21
HK1038008A1 (en) 2002-03-01
CN1177829C (zh) 2004-12-01
PT1076651E (pt) 2005-08-31
WO1999057102A1 (de) 1999-11-11
EP1076651B1 (de) 2005-04-20
DE19820064A1 (de) 1999-11-11
DE59911949D1 (de) 2005-05-25
JP2002513785A (ja) 2002-05-14
HU225377B1 (en) 2006-10-28
KR20010043304A (ko) 2001-05-25
RU2221789C2 (ru) 2004-01-20
NO20005549D0 (no) 2000-11-03
HUP0102459A2 (hu) 2002-03-28
JP4546644B2 (ja) 2010-09-15
PL344041A1 (en) 2001-09-24
DE19980787D2 (de) 2001-03-22
BR9911009A (pt) 2001-02-13
HUP0102459A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
Dekel et al. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
EP1302476A4 (en) REDUCED FK228 AND ITS USE
DE60228954D1 (en) Pyruvatderivate
EA200000409A1 (ru) Соединение, фармацевтическая композиция, способ ингибирования гибели клетки в одной клетке или ткани, способ лечения или снижения клеточной смерти, способ лечения или профилактики поликистозного заболевания почек или анемии/эритропоэза у животных, способ защиты органа или ткани млекопитающего от гибели клеток, способ снижения или профилактики гибели клеток в органе или ткани донора после их трансплантации, способ снижения или предотвращения гибели спермы или яйцеклеток
AP1739A (en) Azaindoles
EA200300205A1 (ru) Производные пиразола и их применение в качестве ингибиторов протеинкиназы
ES2181725T3 (es) Inhibidores de hiv proteasa.
EP1076563A4 (en) DIPEPTID CASPASE INHIBITORS AND THEIR USE
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
GB0106661D0 (en) Pharmaceutically active compounds
SE0202462D0 (sv) Novel use
BR0200782A (pt) Compostos para o tratamento da isquemia
HRP20030448A2 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
MY138341A (en) Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
NZ507964A (en) Substituted sulphonyl cyanamides
GB2272375A (en) Pharmaceutical composition
IS2405B (is) Notkun dextransúlfats til að meðhöndla skyndilegtblóðmiðlað bólguviðbragð (IBMIR)
MY139310A (en) Pentafluorosulfanylbenzoylguanidines, process for their preparation, their use as. medicament or diagnostic aid, and medicament comprising them
BR9814053A (pt) Diésteres lipofìlicos de agentes de quelação
ES2148268T3 (es) Composicion farmaceutica para prevenir o tratar fracturas de huesos.
ES475660A1 (es) Un procedimiento para la preparacion de un tiol acido y sus sales y esteres
RU2002113667A (ru) Применение 2-амино-3,4-дигидрохиназолинов для получения лекарственного средства для лечения и профилактики заболеваний, вызываемых ишемическими состояниями

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)